Johnson & Johnson Hits New 52-Week High at $248.94, Up 68.85%

Johnson & Johnson has reached a significant milestone by hitting a new 52-week high of USD 248.94 on February 27, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it holds a prominent position as a large-cap entity with a market capitalization of USD 702,556 million. Over the past year, Johnson & Johnson has demonstrated impressive growth, with a performance increase of 68.85%, significantly outpacing the S&P 500's 17.36% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 28.00, reflecting its valuation in the market. Additionally, Johnson & Johnson offers a dividend yield of 1.44%, which may appeal to income-focused investors. With a debt-to-equity ratio of 0.34 and a return on equity of 27.89%, the company showcases a solid financial foundation. The price-to-book ratio is recorded at 8.62, indicating the market's valuation of its assets. Overall, Johnson & Johnson's recent performance highlights its robust market position and financial health within the industry.